2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Numbers of People with HIV/AIDS Reported and Not Reported to Surveillance in Japan

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          BACKGROUND: Trends in the numbers of Japanese patients with human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) reported to the HIV/AIDS surveillance system in Japan were examined. We attempted to estimate the cumulative number of Japanese with HIV, including people with HIV not reported to the surveillance.

          METHODS: Data from the HIV/AIDS surveillance in Japan up to the end of 2002 were available. The number of unreported HIV cases was estimated using the back-calculation method. To evaluate this method, the number of reported HIV cases up to 1996 (before highly active antiretroviral treatments were widely available in Japan) was compared with the number estimated by the same method.

          RESULTS: The number of AIDS cases who were initially reported as having AIDS without having been reported as HIV-infected markedly increased as did the number of reported HIV cases. The number of AIDS cases who had been initially reported as HIV-infected and who were then reported as AIDS progression increased up to 1996 but decreased in the period of 1997-2002. The cumulative number of people with HIV at the end of 2002 was estimated as 14,000, which was 4.2 times higher than the number of reported HIV cases. The cumulative number of HIV cases reported up to 1996 was nearly equal to the number estimated by the above-mentioned method.

          CONCLUSIONS: HIV infection would appear to be spreading widely among Japanese population. The number of HIV cases actually reported to surveillance might still be low.

          Related collections

          Most cited references16

          • Record: found
          • Abstract: found
          • Article: not found

          Improved survival among HIV-infected individuals following initiation of antiretroviral therapy.

          Clinical trials have established the efficacy of antiretroviral therapy with double- and triple-drug regimens for individuals infected with the human immunodeficiency virus (HIV), but the effectiveness of these regimens in the population of patients not enrolled in clinical trials is unknown. To characterize survival following the initiation of antiretroviral therapy among HIV-infected individuals in the province of British Columbia. Prospective, population-based cohort study of patients with antiretroviral therapy available free of charge (median follow-up, 21 months). Province of British Columbia, Canada. All HIV-positive men and women 18 years of age or older in the province who were first prescribed any antiretroviral therapy between October 1992 and June 1996 and whose CD4+ cell counts were less than 0.350 x 10(9)/L. Rates of progression from initiation of antiretroviral therapy to death or a primary acquired immunodeficiency syndrome (AIDS) diagnosis for subjects who initially received zidovudine-, didanosine-, or zalcitabine-based therapy (ERA-I) and for those who initially received therapy regimens including lamivudine or stavudine (ERA-II). A total of 1178 patients (951 ERA-I, 227 ERA-II) were eligible. A total of 390 patients died (367 ERA-I, 23 ERA-II), yielding a crude mortality rate of 33.1%. ERA-I group subjects were almost twice as likely to die as ERA-II group subjects, with a mortality risk ratio of 1.86 (95% confidence interval [CI], 1.21 -2.86; P=.005). After adjusting for Pneumocystis carinii and Mycobacterium avium prophylaxis use, AIDS diagnosis, CD4+ cell count, sex, and age, ERA-I participants were 1.93 times (95% CI, 1.25-2.97; P=.003) more likely to die than ERA-II participants. Among patients without AIDS when treatment was started, ERA-I participants were 2.50 times (95% CI, 1.59-3.93; P<.001) more likely to progress to AIDS or death than ERA-II participants. The HIV-infected individuals who received initial therapy with regimens including stavudine or lamivudine had significantly lower mortality and longer AIDS-free survival than those who received initial therapy with regimens limited to zidovudine, didanosine, and zalcitabine.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.

            The efficacy and safety of adding a protease inhibitor to two nucleoside analogues to treat human immunodeficiency virus type 1 (HIV-1) infection are not clear. We compared treatment with the protease inhibitor indinavir in addition to zidovudine and lamivudine with treatment with the two nucleosides alone in HIV-infected adults previously treated with zidovudine. A total of 1156 patients not previously treated with lamivudine or protease inhibitors were stratified according to CD4 cell count (50 or fewer vs. 51 to 200 cells per cubic millimeter) and randomly assigned to one of two daily regimens: 600 mg of zidovudine (or stavudine) and 300 mg of lamivudine, or that regimen with 2400 mg of indinavir. The primary end point was the time to the development of the acquired immunodeficiency syndrome (AIDS) or death. The proportion of patients whose disease progressed to AIDS or death was lower with indinavir, zidovudine, and lamivudine (6 percent) than with zidovudine and lamivudine alone (11 percent; estimated hazard ratio, 0.50; 95 percent confidence interval, 0.33 to 0.76; P=0.001). Mortality in the two groups was 1.4 percent and 3.1 percent, respectively (estimated hazard ratio, 0.43; 95 percent confidence interval, 0.19 to 0.99; P=0.04). The effects of treatment were similar in both CD4 cell strata. The responses of CD4 cells and plasma HIV-1 RNA paralleled the clinical results. Treatment with indinavir, zidovudine, and lamivudine as compared with zidovudine and lamivudine alone significantly slows the progression of HIV-1 disease in patients with 200 CD4 cells or fewer per cubic millimeter and prior exposure to zidovudine.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Minimum size of the acquired immunodeficiency syndrome (AIDS) epidemic in the United States.

              A new method based on the reported incubation period of transfusion-associated AIDS was used to estimate the number of AIDS cases likely to arise in the USA among those infected before 1986. Between 1986 and 1991 102,000 new cases are projected, with a total cumulative incidence of 135,000 AIDS cases. These estimates do not account for new infections after 1985 nor very long incubation periods and are thus the smallest numbers to be expected. Even if new infections can be effectively prevented, the epidemic will be five times larger than the number of cases observed so far.
                Bookmark

                Author and article information

                Journal
                J Epidemiol
                J Epidemiol
                JE
                Journal of Epidemiology
                Japan Epidemiological Association
                0917-5040
                1349-9092
                18 March 2005
                2004
                : 14
                : 6
                : 182-186
                Affiliations
                [1 ]Department of Hygiene, Fujita Health University School of Medicine.
                [2 ]Epidemiology and International Health Research Section, Environmental Health Sciences Division, National Institute for Environmental Studies.
                [3 ]Nagoya City University School of Nursing.
                [4 ]Department of Public Health, Yokohama City University School of Medicine.
                [5 ]Department of Public Health, Jichi Medical School.
                [6 ]Kyoto University School of Public Health.
                [7 ]National Institute of Public Health.
                Author notes

                Address for correspondence: Shuji Hashimoto, Department of Hygiene, Fujita Health University School of Medicine, 1-98, Kutsukake-cho, Toyoake, Aichi 470-1192, Japan.

                This study was supported by a Grant-in-Aid from the Ministry of Health, Labour and Welfare of Japan for Research on HIV/AIDS.

                Article
                14.182
                10.2188/jea.14.182
                8784241
                15617391
                b602cb12-a718-4275-b74c-2fa2ad857bf0
                © 2004 Japan Epidemiological Association.

                This is an open access article distributed under the terms of Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

                History
                : 2 July 2004
                : 18 August 2004
                Categories
                Original Article

                hiv,acquired immunodeficiency syndrome,surveillance,trend,estimation

                Comments

                Comment on this article